Keryx

Beleggen in aandelen beurs New York, Dow Jones index, Nasdaq-100 en S&P500
Plaats reactie
Gebruikersavatar
sanderus
Forum elite
Forum elite
Berichten: 2867
Lid geworden op: 07 Aug 2012 08:47
waarderingen: 3103
Contact:

Re: Keryx

Berichtdoor sanderus » 02 Feb 2018 15:45

piddybull schreef:The world most ...
My IMS guess for today is 1,565

Dan zet John dit als waarheid op Yahoo (wel net weggehaald)

waarna Bio2 ... op ST : IMS 1565 from Yahoo board

:lol: :lol:


Mooi maar we moeten een blijvende stijging zien. 2000 IMS scripts voor 1 maart zou mooi zijn
Revenge 2 liked last!


believer
Forum veteraan
Forum veteraan
Berichten: 1811
Lid geworden op: 14 Jan 2015 17:30
waarderingen: 1002
Contact:

Re: Keryx

Berichtdoor believer » 02 Feb 2018 16:59

Goeie scripts,nu in stijgende lijn en volgende week naar 1650!

Gebruikersavatar
piddybull
Premiummember
Premiummember
Berichten: 1010
Lid geworden op: 21 Jan 2013 22:45
Locatie: Aardbol
waarderingen: 830
Contact:

Re: Keryx

Berichtdoor piddybull » 02 Feb 2018 17:24

Ik blijf het buikgevoel behouden dat er een eerste poster was die 1565 als gok waagde en dat dit getal tot drie maal toe werd overgenomen,de ene maal op Yahoo de ander maal op ST.
Dan eigen leven beginnen lijden.
Of er is gewoon juist gegokt !

Doet er feitelijk niet toe maar wel soap indien het zo zou zijn.

Prettig weekend !
GALAPAGOS - This is just the beginning !

Gebruikersavatar
piddybull
Premiummember
Premiummember
Berichten: 1010
Lid geworden op: 21 Jan 2013 22:45
Locatie: Aardbol
waarderingen: 830
Contact:

Re: Keryx

Berichtdoor piddybull » 02 Feb 2018 22:14

Keryx Biopharmaceuticals to Host Conference Call of Fourth Quarter and Full Year 2017 Financial Results on Wednesday, February 7, 2018

Toch stuk sneller dan voorzien ,niet ??

eerste reactie ST :
Feb 7 earnings call, isn't that quick for KERX? Mo mention in release of "corporate developments" or guidance, just earnings.
sanderus liked last!
GALAPAGOS - This is just the beginning !

Gebruikersavatar
piddybull
Premiummember
Premiummember
Berichten: 1010
Lid geworden op: 21 Jan 2013 22:45
Locatie: Aardbol
waarderingen: 830
Contact:

Re: Keryx

Berichtdoor piddybull » 03 Feb 2018 16:00

BRON: Nasdaq (eco news 03/02/17)

(sterk ingekort niet zo actueel bericht)

http://utahherald.com/clough-capital-pa ... by-864000/

Charles Clough increased its stake in Keryx Biopharmaceuticals Inc (KERX) by 186.35% based on its latest 2017Q3 regulatory filing with the SEC. Clough Capital Partners LP bought 488,800 shares as the company’s stock rose 24.11% with the market. The hedge fund run by Charles Clough held 751,101 shares of the health care company at the end of 2017Q3, valued at $5.33M, up from 262,301 at the end of the previous reported quarter. Clough Capital Partners LP who had been investing in Keryx Biopharmaceuticals Inc for a number of months, seems to be bullish on the $538.89M market cap company. The stock decreased 1.31% or $0.06 during the last trading session, reaching $4.52. About 1.63M shares traded. Keryx Biopharmaceuticals, Inc.
(NASDAQ:KERX) has risen 13.56% since February 3, 2017 and is uptrending. It has underperformed by 3.14% the S&P500.

Investors sentiment decreased to 1.5 in 2017 Q3. Its down 0.47, from 1.97 in 2017Q2. It dived, as 12 investors sold KERX shares while 26 reduced holdings. 14 funds opened positions while 43 raised stakes. 75.60 million shares or 1.12% less from 76.46 million shares in 2017Q2 were reported.
GALAPAGOS - This is just the beginning !

Gebruikersavatar
sanderus
Forum elite
Forum elite
Berichten: 2867
Lid geworden op: 07 Aug 2012 08:47
waarderingen: 3103
Contact:

Re: Keryx

Berichtdoor sanderus » 05 Feb 2018 12:03

piddybull schreef:Keryx Biopharmaceuticals to Host Conference Call of Fourth Quarter and Full Year 2017 Financial Results on Wednesday, February 7, 2018

Toch stuk sneller dan voorzien ,niet ??

eerste reactie ST :
Feb 7 earnings call, isn't that quick for KERX? Mo mention in release of "corporate developments" or guidance, just earnings.


Inderdaad zeer vlug dit jaar. Normaal altijd in maart. Bovendien vkug na de aankondiging.

Afwachten wat er komt...

believer
Forum veteraan
Forum veteraan
Berichten: 1811
Lid geworden op: 14 Jan 2015 17:30
waarderingen: 1002
Contact:

Re: Keryx

Berichtdoor believer » 07 Feb 2018 10:01

Nog 7 cent hoger in nabeurs,zouden ze iets bijzonder te melden hebben?
Mss iets over Europa of een deal?

Gebruikersavatar
piddybull
Premiummember
Premiummember
Berichten: 1010
Lid geworden op: 21 Jan 2013 22:45
Locatie: Aardbol
waarderingen: 830
Contact:

Re: Keryx

Berichtdoor piddybull » 07 Feb 2018 13:11

Press Release
Keryx Biopharmaceuticals Announces Fourth Quarter and Full Year 2017 Financial Results
Fourth quarter 2017 total revenues of $18.7 million, including net U.S. Auryxia® (ferric citrate) product sales of $17.3 million
Full year 2017 total revenues of $60.6 million; net U.S. Auryxia product sales more than doubled in 2017 to $55.5 million, as compared to 2016
BOSTON, Feb. 07, 2018 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today announced its financial results for the fourth quarter and year ended December 31, 2017. The company also reviewed its commercial progress with Auryxia following approval of the medicine’s second indication for the treatment of iron deficiency anemia in adults with chronic kidney disease, not on dialysis.

“In 2017, we brought Auryxia to an increasing number of people with hyperphosphatemia, and with the recent approval of a second indication, we are confident we can bring Auryxia to even more patients living with chronic kidney disease in the coming years,” said Greg Madison, president and chief executive officer of Keryx Biopharmaceuticals. “With approval of a second indication for Auryxia, we believe we are in a unique position to offer patients and their healthcare providers a medicine that can treat two distinct but related complications of chronic kidney disease. Driving growth in both indications is our focus in 2018 and we look forward to continued progress as we build a leading kidney care company.”

2017 Business Highlights

Full year 2017 net U.S. Auryxia product sales were $55.5 million, as compared to $27.2 million for the full year 2016, a 104 percent increase.
Auryxia net U.S. product sales were $17.3 million in the fourth quarter of 2017, as compared to $8.2 million in the same quarter in 2016.
Approximately 30,400 Auryxia prescriptions were reported in the fourth quarter of 2017, these prescriptions represent 6.5 million Auryxia tablets. This compares to approximately 8,700 prescriptions and 1.8 million Auryxia tablets in the fourth quarter of 2016.
Auryxia received U.S. approval for the treatment of iron deficiency anemia in adults with chronic kidney disease, not on dialysis in November 2017 and was launched in the fourth quarter.
Following formulary access expansion in 2017, Auryxia has broad formulary coverage across Medicare Part D and commercial insurance providers with no restrictions. This formulary status applies to both Auryxia indications.
Fourth Quarter and Year Ended December 31, 2017 Financial Results

“The strong prescription demand growth generated in the fourth quarter, coupled with the stabilization of the gross-to-net adjustment, led to $17.3 million of net U.S. Auryxia product sales in the fourth quarter of 2017,” said Scott Holmes, senior vice president and chief financial officer of Keryx Biopharmaceuticals. “As we enter 2018, we believe we will continue to drive Auryxia growth as a chronic kidney disease treatment for both hyperphosphatemia in the dialysis setting, as well as iron deficiency anemia in the non-dialysis setting.”

Total revenues for the quarter ended December 31, 2017 were approximately $18.7 million, compared with $9.5 million during the same period in 2016. Total revenues for the fourth quarter of 2017 consist of approximately $17.3 million in net U.S. Auryxia product sales, as compared to $8.2 million in the fourth quarter of 2016. Total revenues for the fourth quarter of 2017 also include $1.4 million in license revenue, as compared to $1.3 million during the same period in 2016.

For the year ended 2017, total revenues were approximately $60.6 million, as compared to $32.0 million in 2016. Total revenues for 2017 include $55.5 million of Auryxia net U.S. product sales and $5.1 million in license revenue, as compared to $27.2 million and $4.8 million, respectively, in 2016.

Cost of goods sold for the quarter ended December 31, 2017 were $7.4 million, compared with $13.4 million during the same period in 2016. For the year ended 2017, total cost of goods sold were $22.0 million, as compared to $37.8 million in 2016.

Selling, general and administrative expenses for the quarter ended December 31, 2017 were $28.8 million, as compared to $23.0 million during the same period in 2016. For the year ended December 31, 2017, total selling, general and administrative expenses were $99.6 million, as compared to $84.6 million in 2016. Selling, general and administrative expenses for the quarter and full year ended December 31, 2017 included $6.6 million and $15.6 million, respectively, in non-cash stock compensation expense, as compared to $2.8 million and $11.2 million, respectively, during the same periods in 2016.

Research and development expenses for the quarter ended December 31, 2017 were $12.6 million, as compared to $6.2 million during the same period in 2016. For the year ended December 31, 2017, total research and development expenses were $37.7 million, as compared to $29.5 million in 2016. Research and development expenses for the quarter and full year ended December 31, 2017 included $1.0 million and $2.6 million, respectively, in non-cash stock compensation expense, as compared to $0.6 million and $2.8 million, respectively, during the same periods in 2016.

Net loss for the quarter ended December 31, 2017 was $30.4 million, or $0.26 per share, as compared to a net loss of $33.8 million, or $0.32 per share, for the comparable period in 2016. For the full year 2017, net loss was $163.4 million, or $1.43 per share, as compared to $161.1 million, or $1.52 per share, in 2016.

Cash and cash equivalents as of December 31, 2017 totaled approximately $93.5 million.
charel01 liked last!
GALAPAGOS - This is just the beginning !

believer
Forum veteraan
Forum veteraan
Berichten: 1811
Lid geworden op: 14 Jan 2015 17:30
waarderingen: 1002
Contact:

Re: Keryx

Berichtdoor believer » 07 Feb 2018 13:26

Dit lijken mij topresultaten :D !
Vandaag eindelijk vuurwerk?!
emma liked last!

Gebruikersavatar
cicero007
Premiummember
Premiummember
Berichten: 984
Lid geworden op: 22 Mei 2013 09:31
waarderingen: 329
Contact:

Re: Keryx

Berichtdoor cicero007 » 07 Feb 2018 15:28

believer schreef:Dit lijken mij topresultaten :D !
Vandaag eindelijk vuurwerk?!



Ik denk eerder dat we een duik zullen nemen...
If you can't stand the heat, stay out of the kitchen ...